One-Year Clinical and Computed Tomography Angiographic Outcomes after Bioresorbable Vascular Scaffold Implantation during Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction: The Prague-19 Study

Circulation: Cardiovascular Interventions

Volumn 8, Issue 12, 2015, Pages

  Widimsky, Petr ^a   Petr, Robert ^a   Tousek, Petr ^a   Maly, Martin ^a   Linkova, Hana ^a   Vrana, Jiri ^a   Hajsl, Martin ^a   Budesinsky, Tomas ^b   Lisa, Libor ^a   Kocka, Viktor ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CENTRAL MILITARY HOSPITAL   (Czech Republic)

Author keywords

bioresorbable scaffold; computed tomography; myocardial infarction; restenosis; stent; stent thrombosis

Indexed keywords

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BALLOON DILATATION; BIORESORBABLE SCAFFOLD; BIORESORBABLE VASCULAR SCAFFOLD; CARDIOVASCULAR MORTALITY; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DRUG ELUTING STENT; FEMALE; HOME; HUMAN; IMPLANTATION; IN-STENT RESTENOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCREENING; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; SUDDEN DEATH; TREATMENT OUTCOME; AGED; BIODEGRADABLE IMPLANT; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ANGIOGRAPHY; MIDDLE AGED; MYOCARDIAL INFARCTION; RADIOGRAPHY; TISSUE SCAFFOLD;

ABSORBABLE IMPLANTS; AGED; CORONARY ANGIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDIES; TISSUE SCAFFOLDS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84951013767     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.115.002933     Document Type: Article

References (28)

1. Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van 't Hof A, Widimsky P, Zahger D., Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC) ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012 33 2569 2619
2. Stone GW, Lansky AJ, Pocock SJ, Gersh BJ, Dangas G, Wong SC, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Möckel M, Ochala A, Kellock A, Parise H, Mehran R, HORIZONS-AMI Trial Investigators Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med 2009 360 1946 1959. doi: 10.1056/NEJMoa0810116.
3. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, Suddath WO, Weissman NJ, Torguson R, Kent KM, Pichard AD, Satler LF, Waksman R, Serruys PW., Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004 364 1519 1521. doi: 10.1016/S0140-6736(04)17275-9.
4. Lagerqvist B, James SK, Stenestrand U, Lindbäck J, Nilsson T, Wallentin L, SCAAR Study Group Long-Term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007 356 1009 1019. doi: 10.1056/NEJMoa067722.
5. Webster MW, Ormiston JA., Drug-eluting stents and late stent thrombosis. Lancet 2007 370 914 915. doi: 10.1016/S0140-6736(07)61424-X.
6. von Birgelen C, Basalus MW, Tandjung K, van Houwelingen KG, Stoel MG, Louwerenburg JH, Linssen GC, Saïd SA, Kleijne MA, Sen H, Löwik MM, van der Palen J, Verhorst PM, de Man FH., A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: The TWENTE trial. J Am Coll Cardiol 2012 59 1350 1361. doi: 10.1016/j.jacc.2012.01.008.
7. Palmerini T, Biondi-Zoccai G, Della Riva D, Stettler C, Sangiorgi D, D'Ascenzo F, Kimura T, Briguori C, Sabatè M, Kim HS, De Waha A, Kedhi E, Smits PC, Kaiser C, Sardella G, Marullo A, Kirtane AJ, Leon MB, Stone GW., Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-Analysis. Lancet 2012 379 1393 1402. doi: 10.1016/S0140-6736(12)60324-9.
8. Waksman R., Biodegradable stents: They do their job and disappear. J Invasive Cardiol 2006 18 70 74
9. Ormiston JA, Webster MW, Armstrong G., First-in-human implantation of a fully bioabsorbable drug-eluting stent: The BVS poly-L-lactic acid everolimus-eluting coronary stent. Catheter Cardiovasc Interv 2007 69 128 131. doi: 10.1002/ccd.20895.
10. Serruys PW, Onuma Y, Dudek D, Smits PC, Koolen J, Chevalier B, de Bruyne B, Thuesen L, McClean D, van Geuns RJ, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Hebert KM, Sudhir K, Garcia-Garcia HM, Ormiston JA., Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol 2011 58 1578 1588. doi: 10.1016/j.jacc.2011.05.050.
11. Serruys PW, Chevalier B, Dudek D, Cequier A, Carrié D, Iniguez A, Dominici M, van der Schaaf RJ, Haude M, Wasungu L, Veldhof S, Peng L, Staehr P, Grundeken MJ, Ishibashi Y, Garcia-Garcia HM, Onuma Y., A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): An interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet 2015 385 43 54. doi: 10.1016/S0140-6736(14)61455-0.
12. Capodanno D, Gori T, Nef H, Latib A, Mehilli J, Lesiak M, Caramanno G, Naber C, Di Mario C, Colombo A, Capranzano P, Wiebe J, Araszkiewicz A, Geraci S, Pyxaras S, Mattesini A, Naganuma T, Münzel T, Tamburino C., Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention 2015 10 1144 1153. doi: 10.4244/EIJY14M07-11.
13. Serruys PW, Onuma Y, Garcia-Garcia HM, Muramatsu T, van Geuns RJ, de Bruyne B, Dudek D, Thuesen L, Smits PC, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Hebert KM, Rapoza R, Ormiston JA., Dynamics of vessel wall changes following the implantation of the absorb everolimus-eluting bioresorbable vascular scaffold: A multi-imaging modality study at 6, 12, 24 and 36 months. EuroIntervention 2014 9 1271 1284. doi: 10.4244/EIJV9I11A217.
14. Onuma Y, Dudek D, Thuesen L, Webster M, Nieman K, Garcia-Garcia HM, Ormiston JA, Serruys PW., Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: The ABSORB cohort A trial. JACC Cardiovasc Interv 2013 6 999 1009. doi: 10.1016/j.jcin.2013.05.017.
15. Verheye S, Ormiston JA, Stewart J, Webster M, Sanidas E, Costa R, Costa JR Jr, Chamie D, Abizaid AS, Pinto I, Morrison L, Toyloy S, Bhat V, Yan J, Abizaid A., A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6-and 12-month clinical and multimodality imaging results. JACC Cardiovasc Interv 2014 7 89 99. doi: 10.1016/j.jcin.2013.07.007.
16. Kočka V, Malý M, Toušek P, Buděšínský T, Lisa L, Prodanov P, Jarkovský J, Widimský P., Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: A prospective multicentre study 'Prague 19'. Eur Heart J 2014 35 787 794. doi: 10.1093/eurheartj/eht545.
17. Diletti R, Karanasos A, Muramatsu T, Nakatani S, Van Mieghem NM, Onuma Y, Nauta ST, Ishibashi Y, Lenzen MJ, Ligthart J, Schultz C, Regar E, de Jaegere PP, Serruys PW, Zijlstra F, van Geuns RJ., Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction: BVS STEMI first study. Eur Heart J 2014 35 777 786. doi: 10.1093/eurheartj/eht546.
18. Onuma Y, Serruys PW, Perkins LE, Okamura T, Gonzalo N, García-García HM, Regar E, Kamberi M, Powers JC, Rapoza R, van Beusekom H, van der Giessen W, Virmani R., Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: An attempt to decipher the human optical coherence tomography images in the ABSORB trial. Circulation 2010 122 2288 2300. doi: 10.1161/CIRCULATIONAHA.109.921528.
19. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW, Academic Research Consortium Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007 115 2344 2351. doi: 10.1161/CIRCULATIONAHA.106.685313.
20. Brugaletta S, Gori T, Low AF, Tousek P, Pinar E, Gomez-Lara J, Scalone G, Schulz E, Chan MY, Kocka V, Hurtado J, Gomez-Hospital JA, Münzel T, Lee CH, Cequier A, Valdés M, Widimsky P, Serruys PW, Sabaté M., Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: The BVS-EXAMINATION Study (bioresorbable vascular scaffold-A clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction). JACC Cardiovasc Interv 2015 8 1 pt B 189 197. doi: 10.1016/j.jcin.2014.10.005.
21. Kajiya T, Liang M, Sharma RK, Lee CH, Chan MY, Tay E, Chan KH, Tan HC, Low AF., Everolimus-eluting bioresorbable vascular scaffold (BVS) implantation in patients with ST-segment elevation myocardial infarction (STEMI). EuroIntervention 2013 9 501 504. doi: 10.4244/EIJV9I4A80.
22. Gori T, Schulz E, Hink U, Wenzel P, Post F, Jabs A, Münzel T., Early outcome after implantation of Absorb bioresorbable drug-eluting scaffolds in patients with acute coronary syndromes. EuroIntervention 2014 9 1036 1041. doi: 10.4244/EIJV9I9A176.
23. Dudek D, Rzeszutko Ł Zasada W, Depukat R, Siudak Z, Ochała A, Wojakowski W, Przewłocki T, Zmudka K, Kochman J, Lekston A, Gąsior M., Bioresorbable vascular scaffolds in patients with acute coronary syndromes: The POLAR ACS study. Pol Arch Med Wewn 2014 124 669 677
24. Stone GW., Bioresorbable vascular scaffolds: is imaging everything? EuroIntervention 2014 9 1255 1257. doi: 10.4244/EIJV9I11A213.
25. de Graaf FR, Schuijf JD, van Velzen JE, Boogers MJ, Kroft LJ, de Roos A, Reiber JH, Sieders A, Spanó F, Jukema JW, Schalij MJ, van der Wall EE, Bax JJ., Diagnostic accuracy of 320-row multidetector computed tomography coronary angiography to noninvasively assess in-stent restenosis. Invest Radiol 2010 45 331 340. doi: 10.1097/RLI.0b013e3181dfa312.
26. Budoff MJ, Dowe D, Jollis JG, Gitter M, Sutherland J, Halamert E, Scherer M, Bellinger R, Martin A, Benton R, Delago A, Min JK., Diagnostic performance of 64-multidetector row coronary computed tomographic angiography for evaluation of coronary artery stenosis in individuals without known coronary artery disease: results from the prospective multicenter ACCURACY (Assessment by Coronary Computed Tomographic Angiography of Individuals Undergoing Invasive Coronary Angiography) trial. J Am Coll Cardiol 2008 52 1724 1732. doi: 10.1016/j.jacc.2008.07.031.
27. Meijboom WB, Meijs MF, Schuijf JD, Cramer MJ, Mollet NR, van Mieghem CA, Nieman K, van Werkhoven JM, Pundziute G, Weustink AC, de Vos AM, Pugliese F, Rensing B, Jukema JW, Bax JJ, Prokop M, Doevendans PA, Hunink MG, Krestin GP, de Feyter PJ., Diagnostic accuracy of 64-slice computed tomography coronary angiography: A prospective, multicenter, multivendor study. J Am Coll Cardiol 2008 52 2135 2144. doi: 10.1016/j.jacc.2008.08.058.
28. Arbab-Zadeh A, Hoe J., Quantification of coronary arterial stenoses by multidetector CT angiography in comparison with conventional angiography methods, caveats, and implications. JACC Cardiovasc Imaging 2011 4 191 202. doi: 10.1016/j.jcmg.2010.10.011.